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Short-term antidepressant treatment has
long-lasting effects, and reverses stress-
induced decreases in bone features in rats
S. H. Lee1,10, C. A. Mastronardi1,2, R. W. Li3, G. Paz-Filho1,11, E. G. Dutcher4,5, M. D. Lewis4,6, A. D. Vincent7, P. N. Smith3,8,
S. R. Bornstein9, J. Licinio4,6,12 and M. L. Wong4,6,13
Abstract
Antidepressants are among the most-prescribed class of drugs in the world and though weight gain is a common
outcome of antidepressant treatment, that effect is not well understood. We employed an animal model comprised of
2 weeks of chronic restraint stress with antidepressant treatment, followed by diet-induced obesity. We showed that
short-term antidepressant treatment had long-lasting effects, not only leading to weight gain, but also enhancing
trabecular and cortical bone features in rats; therefore, weight gain in this model was different from that of the classic
diet-induced obesity. Late in the post-restraint recovery period, antidepressant-treated animals were signiﬁcantly
heavier and had better bone features than saline-treated controls, when assessed in the distal femoral metaphysis. The
propensity to gain weight might have inﬂuenced the rate of catch-up growth and bone allometry, as heavier animals
treated with ﬂuoxetine also had enhanced bone features when compared to non-stressed animals. Therefore, short-
term antidepressant treatment ameliorated the long-term effects of stress on body growth and bone. Growth and
bone structural features were associated with leptin levels, and the interaction between leptin levels and
antidepressant was signiﬁcant for bone mineral content, suggesting that short-term antidepressants in the context of
long-term diet-induced obesity modiﬁed the role of leptin in bone formation. To our knowledge this is the ﬁrst study
reporting that short-term antidepressant treatment has long-lasting effects in restoring the effects of chronic stress in
body weight and bone formation. Our ﬁndings may be relevant to the understanding and treatment of osteoporosis, a
condition of increasing prevalence due to the aging population.
Introduction
Major depressive disorder (MDD) and obesity are both
common heterogeneous disorders of complex etiology,
and pronounced public health impact1,2. According to the
data from the World Health Organization (WHO), MDD
has become the second most prevalent cause of illness-
induced disability, affecting 350 million people
worldwide3. Concomitantly, obesity is a debilitating epi-
demic, affecting 36.5% of US adults4. Currently, given the
high prevalence of obesity and mood disorders, it is
conceivable that nearly 25% of the cases of obesity may be
attributable to the association with MDD5. Cross-
sectional and longitudinal studies have been conducted
in order to understand the casual relationship between
MDD and obesity6–8. Both disorders have in common the
dysregulation of the hypothalamic–pituitary–adrenal axis,
which is persistently activated during chronic stress9.
In the USA, antidepressant drugs were the second most
prescribed class of drugs in 2011–20144. Weight gain is a
common outcome of antidepressant treatment. The
interplay between MDD, obesity, and antidepressant-
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induced weight gain is complex. Though acute selective
serotonin reuptake inhibitor (SSRI) treatment leads to
weight loss, chronic SSRI treatment may lead to weight
gain10–12. The discontinuation rate for antidepressant
treatment is high within 2 months of treatment initiation,
ranging from 70% for ﬂuvoxamine, to 45% for ﬂuoxetine
(FX) and 40% for sertraline;13–15 thus, the lifetime pre-
valence of antidepressant exposure is very high. Based on
the model that we have described previously16, here we
combined 2-weeks of recurrent restraint stress and anti-
depressant treatment, followed by long-term diet-induced
obesity; and referred it as the stress-antidepressant and
diet-induced obesity (SADIO) model.
We hypothesized that increased body weight related to
antidepressant treatment in the SADIO model had dif-
ferent pathophysiological mechanisms from those of the
diet-induced obesity model. In the SADIO model
described in this paper, we show that previously described
body changes in the post-stress acclimation and recovery
period17 included increased bone length, weight and
structural changes. Furthermore, there was a signﬁcant
association between leptin and bone mineral content
(BMC) in the SADIO model, which was not present in
animals not exposed to antidepressants.
Methods and materials
Animals
Male Sprague-Dawley rats (170–190 g, 5–6 weeks old,
Animal Resources Centre, Murdoch, WA, Australia) were
housed one per cage at 24 °C and with a 12-h light/dark
schedule (07:00 h to 19:00 h) in a stress-free environment.
All the animal experimental procedures conducted were
approved under protocol number J.MB.50.10, Animal
Experimentation Ethics Committee, The Australian
National University, Australia.
SADIO animal paradigm
Animals were randomly allocated into four groups:
three received chronic restraint-stress (CRS) and one
group did not receive CRS (NR group, N= 30). The NR
group did not receive CRS or intraperitoneally (i.p.)
injections, but received the same dietary schedule as the
CRS groups. For overview of the experimental protocol
see supplementary Figure S1. Prior to CRS, there was no
signiﬁcant difference in body weight between the
groups. CRS was applied from experimental days 5 to 19
for 6 h (from 9:00 to 15:00 h) using ﬂat-bottom clear
acrylic restrainers (Cat no. 544-RR Plas Labs, Lansing,
MI, USA). During the CRS period, CRS groups received
daily treatment with imipramine [IM, N= 13, 10 mg/kg
i.p.; Sigma-Aldrich, St Louis, MO, USA], ﬂuoxetine (FX,
N= 14, 10 mg/kg ip; Eli Lilly, Indianapolis, Indiana,
USA) or saline solution (CS, N= 10, 0.9% sodium
chloride solution ip, Phebra, Lane Cove West, NSW,
Australia) immediately prior to the CRS procedure.
Imipramine was prepared in 24.5 mg/mL in 0.9%
sodium chloride solution by mild vortexing and pH was
adjusted to 7.4. The solution was further diluted and the
ﬁnal concentration of the imipramine was 4.9 mg/mL in
0.9% sodium chloride solution. Fluoxetine hydro-
chloride was prepared 5.6 mg/mL in 0.9% sodium
chloride due to its low solubility and pH was adjusted to
7.4. The solution was further diluted to ﬁnal con-
centration of 4.9 mg/mL in 0.9% sodium chloride solu-
tion. Solutions were ﬁltered with a 0.22-μm ﬁlter (EMD
Millipore™SLGP033RS, Ontario, Canada). After the CRS
period, all groups of animals received a high-fat diet
(18.6% fat semi-pure rodent diet SF10-020, Specialty
Feeds, Glen Forrest, WA, Australia) to induce obesity
from day 19 to 296 (276 days). Researcher could not be
blinded to the experimental groups as daily i.p. injection
of speciﬁc treatment group was necessary from days 5 to
19. We did not conduct power analysis prior to this
study as there was no study using our animal model for
2 weeks of CRS followed by induced obesity from day 19
to 296. Body weight and food intake were measured
daily during the CRS period and twice weekly thereafter.
Due to the fact that rodents, such as Sprague-Dawley
rats, display variable weight gain when fed a high-fat
diet, animals were classiﬁed into subgroups of animals
that gain signiﬁcant weight (obesity prone) or not
(obesity resistant)18. Therefore, we conducted analyses
to understand whether the ability to gain weight during
diet-induced obesity had signiﬁcant effects in our
model. Within each group, rats in the upper 50% of body
weights were classiﬁed as the obesity-prone subgroup
based on their body weight at the end of the experiment,
and animals in the lower 50% were classiﬁed as the
obesity-resistant subgroup.
Behavioral testing
Open-ﬁeld tests and elevated plus maze were conducted
during the post-stress acclimation period (experimental
weeks 3–12), equipped with a camera tracking system
(Viewer II system, Biobserve GmbH, Bonn, Germany).
Open-ﬁeld test: Trials were conducted for 30min/sessions
from 11:00 to 16:00 h. Rats were placed in the center of the
ﬁeld (48.8 cm × 48.8 cm × 50 cm). Total distance (TD),
center distance (CD), and center distance to total distance
(CD/TD) ratio were obtained and used as an index of
anxiety16. Groups were CRS treated with saline, N= 11;
FX, CRS treated with ﬂuxotine, N= 14, and IM, CRS
treated with imipramine, N= 11. Their means were sub-
sequently averaged along the 10 sessions. Elevated plus
maze (EPM): During the post-stress acclimation period
(day 257), EPM test was performed to measure the level of
anxiety-like behavior. EPM was elevated from the ﬂoor
with two open arms and two closed arms (50 cm × 13 cm).
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Rats were placed in the middle of the maze facing a closed
arm; trials were conducted for 5min/session. The number
of entries into the open arms was counted and the per-
centage of time spent in the open arms (ratio of open arms
time/closed arms time) was calculated. The groups were
CS, N= 11; FX, N= 12; IM, N= 11. Researchers were
blinded while conducting behavioral tests.
Dual energy X-ray absorptiometry (DXA) for body
composition analysis and body length measurements
Body composition analysis of subsets of obesity-prone
(upper 30%) and obesity-resistant (lower 30%) animals
were obtained under anesthesia using the GE Lunar
PIXImus equipment (Madison, WI, USA) and the Lunar
imaging software (ver.1.46) according to standard proce-
dures (see supplementary methods for detailed metho-
dology). The groups were CS, N= 4; FX, N= 5; IM, N=
4; NR, N= 10.
Microtomography (Micro-CT)
Micro-CT imaging of hind femurs was obtained from
all animals using the Skyscan micro-CT equipment
(Bruker, Kontich, Belgium). Distal femora were scanned
submerged in 70% ethanol at a resolution of 21.3 μm.
Transverse plane images were obtained from recon-
structed images using the DataViewer software (Sky-
scan), and distal metaphyseal volume and mid-
diaphyseal cortical geometry were generated by a
binarized image program (CtAnalyzer software, Sky-
scan) (see supplementary methods for detailed metho-
dology). The groups were CS, N= 10; FX, N= 14; and
IM, N= 13, groups. NR, N= 28.
Quantitative real time PCR (qPCR)
cDNA samples were tested in triplicate for the following
rat genes: rat Igf1 in liver tissue, groups were CS, N= 9;
FX, N= 12; IM, N= 13; NR, N= 25; and 8 target genes in
adipose tissue: Tnf, Slc2a4, Pparg, Adipoq, Fasn, Lpl, Lipe,
and Ppargc1a (see supplementary methods for detailed
methodology and primer sequences), groups were NR, N
= 11; IM, N= 11; FX, N= 12; and CS, N= 8.
Immunoassays
Commercial immunoassay kits were used to determine
plasma IGF-1(CS, N= 7; FX, N= 8; IM, N= 8; NR, N=
16), leptin (CS, N= 10; FX, N= 14; IM, N= 13; NR N=
30), triglyceride (CS, N= 10; FX, N= 14; IM, N= 13; NR,
N= 27), total cholesterol (CS, N= 10; FX, N= 14; IM, N
= 13; NR, N= 30), free fatty acid (CS, N= 10; FX, N= 14;
IM, N= 13; NR, N= 30), vanillylamandelic acid (CS, N=
10; FX, N= 14; IM, N= 13; NR, N= 26), and pituitary
GH (CS, N= 6; FX, N= 7; IM, N= 6; NR, N= 10), fol-
lowing the manufacturers’ protocols (see supplementary
methods for detailed methodology).
Statistical analysis
Piecewise non-linear mixed effects growth curve models
were constructed to estimate rat weights, y, post-stress
over two periods: (A) days 20–60 and (B) day 60 onward.
Analyses performed in R v3.4.1 (Vienna, Austria) using
the nlme package (see supplementary methods for
detailed statistical analysis)19.
Group comparisons were done by one-way analysis of
variance (ANOVA) or non-parametric test of Kruskal-
Wallis when the variances were not equal among treat-
ment groups, and respectively followed by Tukey’s or
Dunn’s post hoc test, using the GraphPad Prism 5.0 soft-
ware (La Jolla, CA, USA) (see supplementary methods for
detailed statistical analysis).
Associations between the ﬁve body composition out-
comes [bone mineral content (BMC), bone mirenal den-
sity (BMD), % fat, body length, body weight) with four
biochemical measures (log-transformed plasma leptin,
total cholesterol, triglyceride, and fatty acids levels) were
tested using linear regressions (see supplementary meth-
ods for detailed statistical analysis).
Results
Two-week antidepressant treatment improves body
weight recovery during the post-stress period
Immediately post CRS, groups treated with FX, imi-
pramine (IM) or vehicle (CS) had signiﬁcantly lower body
weight (β^
1
0 all P < 0.001) than the non-stressed reference
(NR) group (SI Appendix, Table S1A). During the post
CRS period, the group treated with FX gained more body
weight than the saline control (CS) group (Table S1 B, P
= 0.03). Furthermore, the FX group became heavier than
the NR group (Fig. 1a, b). We did not detect differences in
the weights of the IM and CS-treated rats (P= 0.10).
Chronic stressed obesity prone and obesity resistant
subgroups treated with antidepressant had better weight
recovery in the post-acclimation period
The log-likelihood ratio tests indicated the presence of
interactions between treatment and obesity-prone groups
in both periods (both P < 0.0001; SI Appendix, Table S1
BC). In the obesity-prone (upper 50% body weight) sub-
groups, the FX-treated group gained more body weight
than the other CRS-treated groups (obesity prone: CS vs
FX P < 0.0001, IM vs FX P= 0.01; Fig. 1c, and SI
Appendix Table S1 B). In contrast, amongst the obesity-
resistant (lower 50% body weight) stressed subgroups,
body weights did not differ (Fig. 1d, and SI Appendix
Table S1 B).
Chronic stressed FX-treated animals were less anxious
During the post-restraint stress period (weeks 3–12), we
conducted behavioral tests on animals that had under-
gone CRS. The FX group was signiﬁcantly less anxious
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Fig. 1 The effect of chronic restraint stress (CRS) and antidepressant on long-term weight gain and effect on classiﬁed subgroups of
obesity prone (OP) and obesity resistant (OR) groups a Body weight for all groups during experimental days 3 to 296. CRS occurred in the CS
(control CRS treated with saline, N= 10), FX (CRS treated with ﬂuxotine, N= 14), and IM (CRS treated with imipramine, N= 13) groups between
experimental days 5–19 (grey shaded area, CRS+ antidepressant treatment, AD), followed by a high-fat diet from experimental days 19–296. b–d The
graph represents the comparison of the difference in body weight [body weight of antidepressant-treated group (FX, N= 14 and IM, N= 13)—non-
restraint reference group (NR, N= 30)] in reference to difference in body weight of the restraint saline-treated control group [body weight of saline-
treated control group (CS, N= 10)—non-restraint reference group (NR= 30)]. CRS occurred in the CS, FX, and IM groups between experimental days
5–19 (grey shaded area), followed by a high-fat diet from experimental days 19–296. (B) Difference in body weight of all groups, c difference in body
weight of OP subgroups, (D) difference in body weight of OR subgroups. *P < 0.05, **P < 0.01, ***P < 0.001
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than the CS group, based on the open ﬁeld test measure of
CD/TD ratio, and on the open/closed arm ratio on the
elevated plus maze test (both P < 0.05, Fig. 2a, b, and SI
Appendix, Table S2).
Bone morphological features were enhanced in chronic
stressed antidepressant-treated animals
Our ﬁndings support that the FX group had sig-
niﬁcantly enhanced trabecular and cortical bone micro-
CT features (Fig. 3a). Percentage of trabecular bone
volume/total volume ratio (BV/TV %), and trabecular
thickness and number were signiﬁcantly greater in the FX
group in comparison to the NR group (respectively, P <
0.01, P < 0.05, and P < 0.05, Fig. 3a–d, and SI Appendix,
Table S3). Cortical bone features, such as mean total
cross-sectional bone area and thickness, were also sig-
niﬁcantly greater in the FX group in comparison to the
NR group (respectively, P < 0.01, P < 0.001, and Fig. 3e, f,
and SI Appendix, Table S3). The FX group also had mean
total cross-sectional thickness signiﬁcantly greater than
the CS groups (P < 0.05, Fig. 3f, and SI Appendix, Table
S3). The femur length was signiﬁcantly greater in the IM
in comparison to the CS group (P < 0.05, Fig. 3g, and SI
Appendix, Table S3).
Hepatic Igf1 (insulin growth factor 1) mRNA levels were
increased in chronic stressed animals
At the end of the experiment, hepatic Igf1 gene
expression was signiﬁcantly higher in all CRS groups in
comparison to the NR group (P < 0.05 for CS and FX, and
P < 0.01 for IM, Fig. 3h, and SI Appendix, Table S2).
However, IGF-1 and growth hormone (GH) plasma levels
were not signiﬁcantly different between the groups
(respectively, Fig. 3I, j, and SI Appendix, Table S2).
Chronic stressed obesity prone saline-treated animals had
lower body weight and accumulated food intake, and
higher food intake ratio
Obesity-prone subgroups had signiﬁcantly different
body weight and accumulated higher food intake at the
end of the experiment. Obesity-prone stressed animals
treated with vehicle (obesity prone CS) were signiﬁcantly
lighter than obesity-prone FX and obesity-prone NR
animals (Fig. 4a, respectively, P < 0.05 and P < 0.01, and SI
Appendix, Table S2), and their accumulated food intake
was also signiﬁcantly lower (Fig. 4b, both at P < 0.05, and
SI Appendix, Table S2). Food efﬁciency (food intake/Δ
body weight) of the obesity-prone FX subgroup was sig-
niﬁcantly lower than the obesity-prone CS and obesity-
prone NR subgroups, while obesity-prone IM subgroup
was signiﬁcantly lower than the obesity-prone NR sub-
group (Fig. 4c, P < 0.05, P < 0.001, and P < 0.05, respec-
tively, and SI Appendix, Table S2).
Chronic stressed obesity prone saline-treated animals had
lower lean and fat mass
Obesity-prone stressed animals treated with saline
(obesity-prone CS) had signiﬁcantly lower lean mass and
fat mass in comparison to the obesity-prone NR sub-
group, and lower lean mass than obesity-prone FX ani-
mals (respectively, P < 0.05, P < 0.01, P < 0.001, Fig. 4d, e,
and SI Appendix, Table S2). The obesity-prone IM sub-
group also had lower lean mass than the obesity-prone
NR and the obesity-prone FX subgroups (respectively,
P < 0.05 and P < 0.001, Fig. 4d, and SI Appendix, Table
S2). However, there were no signiﬁcant differences
between the obesity-resistant subgroups in body weight,
accumulated food intake, and food efﬁciency (SI Appen-
dix, Table S2).
Fig. 2 Interaction between exposure to chronic restraint stress (CRS), short-term antidepressant treatment and high-fat diet, and effects
on anxiety and locomotor activity during the post-restraint stress period a Locomotor activity in the open ﬁeld. (CD/TD) ratio in the openﬁeld
box during 30 min of locomotor activity testing; CS, CRS treated with saline, N= 11; FX, CRS treated with ﬂuxotine, N= 14, and IM, CRS treated with
imipramine, N= 11. b, c Elevated plus maze. b Time spent in open arm to closed arm ratio. c Number of entries into open arm. CS, N= 11; FX, N=
12; IM, N= 11. Results are shown as means ± s.e.m. *P < 0.05
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Fig. 3 Effect of chronic restraint stress (CRS) and antidepressants on femoral bone morphology, and insulin-like growth factor 1 (IGF1) and
growth hormone (GH) measurements during post-stress acclimation period a–d Trabecular bone analysis: a micro-computed tomography (CT)
images of trabecular and cortical bones, b trabecular bone volume/total volume %, BV/TV %, c trabecular thickness, d trabecular number. e, f Cortical
bone analysis: e mean total cross sectional bone area and f bone cross sectional thickness obtained from micro-CT analysis. CS, CRS treated with
saline, N= 10; FX, CRS treated with ﬂouxetine, N= 14, and IM CRS treated with imipramine, N= 13, groups. NR, non-CRS reference group, N= 28. g
Femur length CS (n= 10), FX (n= 14), IM (n= 13), NR (n= 29). h Comparison of mean Igf1/Gapdh gene expression between treatments, CS, N= 9;
FX, N= 12; IM, N= 13; NR, N= 25. i IGF1 plasma concentration (ng/mL), CS, N= 7; FX, N= 8; IM, N= 8; NR, N= 16. j GH pituitary concentration (mg/
mL), CS, N= 6; FX, N= 7; IM, N= 6; NR, N= 10. Results are shown as means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001
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Chronic stressed obesity prone saline-treated animals had
worse bone features, and obesity prone FX-treated
animals had enhanced bone features and axial length
Stressed animals treated with saline (obesity-prone CS)
had lower BMD and BMC in the DXA scan, in compar-
ison to the obesity-prone NR and obesity-prone FX sub-
groups (respectively, BMD: P < 0.01, P < 0.01, and BMC: P
< 0.001, P < 0.001, Fig. 4f–g, and SI Appendix, Table S2).
Obesity-prone FX-treated animals had increased axial
length in comparison to the other obesity-prone sub-
groups (P < 0.01 for all comparisons, Fig. 4h, and SI
Appendix, Table S2). Within obesity-resistant groups,
there was no signiﬁcant difference in axial length, fat
mass, BMD, or BMC (SI Appendix, Table S2).
Fig. 4 The effect of chronic restraint stress (CRS) and antidepressant on body weight and composition during post-stress acclimation
period a Body weight of OP animals on day 296. b Accumulated food intake in obesity prone animals. CS, CRS treated with saline N= 5; FX, CRS
treated with ﬂuxotine, N= 7, and IM, CRS treated with imipramine, N= 7, groups. NR, non-CRS reference group, N= 15. c–g DXA (Dual energy x-ray
absorptiometry scan) data for OP animals prior to euthanasia. c Lean mass, d fat mass, e bone mineral density, f bone mineral content, and g body
length, CS, N= 4; FX, N= 5; IM, N= 4; NR, N= 10. H Femur length, CS, N= 10; FX, N= 14; IM, N= 13; NR, N= 29. i Plasma leptin level, CS, N= 5; FX,
N= 7; IM, N= 7; NR N= 15. Results are shown as means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001
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Chronic stressed obesity prone FX-treated animals had
increased leptin plasma levels and were associated with
body composition outcomes
Within CRS obesity-prone subgroups, plasma leptin
level was signiﬁcantly elevated in the FX obesity-prone
subgroup compared to the CS obesity-prone subgroup (P
< 0.05, Fig. 4i, and SI Appendix, Table S2). Leptin was
strongly associated with all ﬁve body composition out-
comes: BMC, BMD, fat percentage, body length, and body
weight (respectively, P= 0.001, P= 0.009, P < 0.0001, P <
0.0001, and P < 0.0001, Fig. 5a–e, and SI Appendix, Table
S4). The interaction between leptin and antidepressant
treatment was signiﬁcant for BMC (P= 0.009, Fig. 5f–h,
and SI Appendix, Table S4). We also found weak evidence
for an interaction between triglycerides and anti-
depressant treatment in body length (P= 0.05, SI
Appendix, Table S4).
Triglyceride plasma levels were lower in chronic stressed
saline- and FX-treated animals
In all the groups, we measured plasma lipid proﬁle (SI
Appendix, Fig. S2), and we found that only triglyceride
level was signiﬁcantly different; CS and FX groups had
lower tryglyceride levels in comparison to the NR group
(Fig. S3A, P < 0.001 and P < 0.05, respectively).
Chronic stressed antidepressant-treated animals had
increased lipolysis in white adipose tissue
The relative expression levels for the 8 target genes were
quantiﬁed in epididymal fat pad samples using qPCR. No
signiﬁcant differences were observed between groups in
the level of expression of any of the genes of interest
except for the Lipe gene, for which the IM and FX groups
were found to have a higher mean expression level than
the NR group (Fig. S4, and SI Appendix, Table S5).
Discussion
Weight gain is a common outcome of antidepressant
treatment in the clinical setting, but several studies have
shown that chronic administration of various anti-
depressants results in failure to gain weight or “para-
doxical” weight loss in rats, especially at high doses20,21.
Until recently, the lack of an appropriate animal paradigm
caused gaps in the understanding of the pathways
involved in antidepressant-induced weight gain in clinical
populations. We have developed the SADIO model to
help expand our understanding of the interface between
obesity, MDD, and antidepressants. This model has
allowed the understanding of the long-term impact of the
combined effects of limited exposure to recurrent stress
and antidepressant (2 weeks), followed by chronic intake
of high-fat diet (>9 months) on body composition and
bone morphology. In this study, we evaluated body weight
recovery patterns, body composition, bone features,
biochemical and gene expression measurements during
the post-stress acclimation period, which is a recovery
phase in which the animal is free from the stressor
exposure17. In agreement with previous literature, 2 weeks
of CRS induced signiﬁcant weight loss in our animals (SI
Appendix, Fig. S2)22. Within the studied timeframe, the
control (CS) group did not attain full body weight
recovery in comparison to the NR group, while both
antidepressant-treated groups had much better body
weight recovery. The ability of the SADIO model to
recover from CRS-induced weight loss during the post-
stress acclimation period could be referred to as a phe-
nomenon of “catch-up growth”, which is growth that
occurs after a period of growth-inhibiting conditions23.
Our results suggest that CRS and antidepressant treat-
ment resulted in a period of greater rate of catch-up
growth during the post-stress acclimation period. The IM
group made full body weight recovery and the FX group
had an exacerbated body weight recovery, recovery
weights of the FX groups were signiﬁcantly larger than
that of the CS group. These ﬁndings suggest that
antidepressant-treated groups had better compensatory
responses that are associated with induction of hyper-
phagia, elevated body weight, and repletion of energy
reserves leading to super abnormal linear growth23.
We found that the obesity-prone FX animals had
increased caloric intake, were lengthier and heavier, and
had increased leptin levels, yet had signiﬁcantly lower
food intake ratio, suggesting that they had greater ability
to store energy. The exacerbated weight gain in the FX
group was associated with signiﬁcant increase in lean
mass, BMD, and BMC, and pronounced positive changes
in bone cortical and trabecular morphology. Congruently,
9 months (endpoint) after stress and antidepressant use
were ceased in the SADIO model, the obesity-prone FX
subgroup had signiﬁcantly greater body length in com-
parison to the obesity-prone NR and obesity-prone CS
subgroups, implying that the propensity to gain weight
can inﬂuence the rate of catch-up growth and bone
allometry. On the other hand, although plasma leptin
level was elevated in the obesity-prone FX subgroup in
comparison to the obesity-prone CS subgroup, the
obesity-prone FX subgroup did not have signiﬁcant
increase in fat mass; yet, the fat mass was signiﬁcantly
lower in the obesity-prone CS subgroup in comparison to
the obesity-prone NR subgroup. Furthermore, the meta-
bolic and lipid plasma proﬁles were not signiﬁcantly ele-
vated in the FX group, suggesting that there was no
further metabolic/lipid dysregulation associated with FX-
induced weight gain (SI Appendix, Fig. S3). Our gene
expression data suggest that it is unlikely that adipose
tissue inﬂammation and metabolism were meaningfully
altered by antidepressant treatment in the SADIO para-
digm, as we found no group differences in the expression
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p <0.001 p <0.009 p <0.0001
p <0.0001
p <0.009 NS NS
p <0.0001
Fig. 5 Associations between leptin and body composition outcomes a BMC, bone mineral content; b BMD, bone mineral density; c fat
percentage; d BL, body length; e body weight. NR= non-restraint control group, N= 30; CS= chronic restraint stress (CRS) group treated with saline,
N= 8; AntiD= CRS+ antidepressant-treated group, N= 17. f–h The interaction between leptin and BMC with its treatment outcomes; f leptin levels
were strongly associated with BMC in the ﬂuoxetine- (FX) and imipramine- (IM) treated animals; leptin levels were not signiﬁncantly associated in the
g CS group and in the h NR group. AntiD= includes FX and IM
Lee et al. Translational Psychiatry            (2019) 9:10 Page 9 of 12
of genes that indicate adipose tissue inﬂammation (Tnf)
and insulin sensitivity (Slc2a4, Adipoq and Pparg).
Moreover, the expression of a gene involved lipolysis
(Lipe) was signiﬁcantly elevated in the FX and IM groups,
indicating that there may have been enhanced lipolysis
activity in these groups.
The literature on the effect of long-term ﬂuoxetine use
on bone metabolism remains controversial. Ortuno
et al.24 have shown that long-term FX treatment results in
serotonin-dependent rise in sympathetic output that
increases bone resorption sufﬁciently to counteract the
local anti-resorptive effect. Our result shows that FX
treatment and stress for 2 weeks in the context of long-
term high-fat diet (over 276 days) resulted in increased
body weight and length, accompanied by enhanced
femoral bone features. Thus, the mechanism of SSRI
action on bone after its discontinuation, in the presence of
high-fat diet, is likely to be different from that of SSRI
treatment alone, as our ﬁndings of elevated BV/TV and
trabecular number are compatible with both reduced
bone resorption, intensiﬁed bone formation (greater tra-
becular thickness) and increased cortical bone features
and bone/body length suggesting enhanced bone growth.
Regardless of treatment duration, antidepressant treat-
ment most likely played a role during catch-up growth in
the post-stress acclimation period. Furthermore, there
was a strong correlation between plasma leptin level and
BMC in the antidepressant-treated groups, which was
absent in the NR or the CS control groups. Both, per-
ipheral and central effects of leptin have been described to
play a role in bone formation25,26. Peripheral leptin has
been reported to have direct bone anabolic function and
increase osteoblast number and activity27; however, via an
indirect hypothalamic-mediated pathway, centrally leptin
inhibits bone formation by regulating both phases of bone
remodeling, resorption and, formation28–30, which sug-
gest that short-term antidepressant treatment either les-
sened the central inhibitory and/or enhanced the
peripheral role of leptin in bone formation in the SADIO
model, resulting in enhanced bone features.
Weight gain can be induced by mechanisms other than
increased fat mass, and growth induced via the GH/IGF1;
somatotropic axis is an important factor in weight gain.
Wu et al. (2009) demonstrated that the over-expression of
systemic IGF1 resulted in enhanced morphological bone
features that resemble those of the SADIO model, such as
increased cortical thickness and total bone mineral den-
sity, and enhanced trabecular bone volume31,32. However,
we found no signiﬁcant differences in the endpoint IGF-1
plasma level between the groups; nevertheless, the
secretion of GH declines with age and GH/IGF-1 levels
may have been different in the earlier stage of weight
gain33,34.
In this study, we show that IGF1 mRNA levels in the
liver are elevated in the CS group than in comparison to
the NR group. Although there was no signiﬁcant differ-
ence in systemic IGF-1 level between the groups, sig-
niﬁcantly lower IGF1 mRNA level in liver in NR group
could provide explanation that NR group did not have
enhanced bone morphological features compared to CS
group. Sjögren et al. (2002) showed that inactivation of
liver IGF1 induced a decrease in cortical cross-sectional
area and periosteal circumference in the mid-diaphyseal
region of the femur and was associated with weaker bone
in the mechanical loading test35. Thus, weight gain of NR
group could be due to diet-induced obesity rather than
the growth associated with enhanced bone morphological
features.
Previous ﬁndings have suggested that short-term FX
treatment induces weight loss36. While on the one hand,
serotonin receptors 5-HT2A and 5-HT2c have been pro-
posed to play a signiﬁcant role in the inhibition of appetite
and food intake37, on the other hand, long-term FX
treatment has been shown to lead to weight gain10–12,36,38.
Despite numerous studies, the effects of FX treatment in
weight regulation remain elusive. Adherence to anti-
depressant treatment is low; in a large European study of
7525 patients, 56% abandoned treatment within
4 months, and weight gain was a major side-effect of
antidepressant. Antidepressants including mirtazapine39,
paroxetine40, and amitriptyline41 have been associated
with long-term weight gain, and meta-analysis showed
that amitriptyline and paroxetine induced the greatest
weight gain in periods over 4 months;36 thus, future
investigations could address the effects of these anti-
depressant drugs on weight regulation in the SADIO
model.
There are several limitations and future directions for
this study. Although our study indicated that stress and
antidepressant (SAD)-induced weight gain is associated
with growth, we could not clearly show whether the
somatotropic axis is involved. We only measured GH/
IGF-1 levels at the end of the experiment and as animals
got older, the growth rate was sustained at much slower
rate than in earlier periods. In the future, pulsatile GH
levels in plasma should be characterised during an earlier
period when a higher growth rate is observed, in order to
obtain a better understanding of the mechanism behind
SAD-related weight gain.
In the SADIO model, 6 h of CRS unavoidably may have
resulted in food deprivation. Although restraint stress was
applied during the light cycle, the effects of food restric-
tion experience on diet-induced weight gain and bone
formation cannot be ruled out. For future studies, one
additional group with 6 h of food deprivation should be
included in the experimental design.
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Our ﬁndings of decreased bone structural features after
stress are compatible with those described for major
depression and chronic stress-induced depressive-like
behavior leading to bone loss42–45. Furthermore, Yirmiya
R et al. (2006) have shown that chronic stress decreased
osteoblast numbers and bone formation via activation of
the sympathetic nervous system, and co-treatment with
IM attenuated bone loss only in animals that improved
from depressive-like behaviors (responders)45. However,
to our knowledge this is the ﬁrst report on the long-
lasting effects of short-antidepressant treatment in body
growth and bone features, which may manifest dissim-
ilarly in subsets of the population with different pro-
pensity to gain weight while consuming high-fat diets. As
osteoporosis is a condition with signiﬁcant morbidity and
increasing prevalence due to the aging population46,47,
our ﬁndings demonstrating that environmental factors
may modulate the role of leptin, may contribute to the
understanding of aspects relevant to the heterogeneity
and treatement approaches of this condition48.
This study has several key ﬁndings: (1) Weight gain after
recurrent stress and short-term antidepressant treatment
followed by diet-induced obesity is different from that of
the classic diet-induced obesity. (2) Short-term anti-
depressant treatment has long-term consequences, and
ameliorated the effects of chronic stress on body growth
(FX), had long lasting effects in anxiety-like behavior (FX)
and adipose tissue gene expression (FX and IM), and
affected bone allometric processes that lead to exacer-
bated bone growth (FX/axial and IM/femur) and
enhanced bone structural features (FX). (3) Those effects
on body growth and bone features are highly associated
with leptin levels. (4) There is a signiﬁcant interaction
between short-term antidepressant treatment and leptin,
that likely lessened the central role of leptin in inhibiting
bone formation; thus, pharmacological agents may inﬂu-
ence the role of leptin in long-term bone regulation.
Clinical studies monitoring body weight, caloric intake,
and body and bone features after antidepressant dis-
continuation are needed to conﬁrm our observations in
the clinical setting.
Acknowledgements
We thank Andrea Stojakovic and Shuyu Guo for assisting with animal
experiments. This work was supported by grant APP1070935 (to MLW and SRB)
from the National Health and Medical Research Council (Australia) and
institutional funds from the Australian National University, the South Australian
Health and Medical Research Institute, and Flinders University.
Author details
1John Curtin School of Medical Research, College of Health and Medicine,
Australian National University, Canberra, ACT 0200, Australia. 2Neuroscience
Group (NeUROS), Institute of Translational Medicine, School of Medicine and
Health Sciences, Universidad del Rosario, Bogotá, Colombia. 3Trauma and
Orthopaedic Research Laboratory, Department of Surgery, Medical School,
Australian National University, Canberra, ACT 0200, Australia. 4Mind & Brain
Theme, South Australian Health and Medical Research, Adelaide, PO Box 11060,
Adelaide, SA 5001, Australia. 5School of Medicine, University of Adelaide,
Adelaide, SA 5005, Australia. 6Flinders University College of Medicine and
Public Health, Bedford Park, SA 5042, Australia. 7Freemasons Foundation
Centre for Men’s Health, Department of Medicine, School of Medicine,
University of Adelaide, Adelaide, SA 5005, Australia. 8Clinical Orthopaedic
Surgery, The Canberra Hospital, Yamba Drive, Garran, ACT 2605, Australia.
9Medical Clinic III, Carl Gustav Carus University Hospital, Dresden University of
Technology, Fetscherstraβe 74, 01307 Dresden, Germany. 10Present address:
Section on Neural Gene Expression, National Institute of Mental Health,
Building 49, Room 5A51, 49 Convent Drive, Bethesda, MD 20892, USA.
11Present address: Janssen Australia, 1-5 Khartoum Rd, North Ryde, NSW 2113,
Australia. 12Present address: State of New York University, Upstate Medical
University, Ofﬁce of the Dean of Medicine, Room 1256 Weiskottem Hall, 766
Irving Ave, Syracuse, NY 13210, USA. 13Present address: State of New York,
Upstate Medical University, 3738C NRB 505 Irving Ave, Syracuse, NY 13210, USA
Conﬂict of interest
G.P.F. is currently employed by Janssen Australia and New Zealand (Janssen-
Cilag Pty Ltd), which is in the business of commercializing therapeutics for
depression.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-018-0351-z).
Received: 2 April 2018 Revised: 1 August 2018 Accepted: 9 December 2018
References
1. Kupfer, D. J., Frank, E. & Phillips, M. L. Major depressive disorder: new clinical,
neurobiological, and treatment perspectives. Lancet 379, 1045–1055 (2012).
2. American Medical Association (AMA). Recognition of obesity as a disease.
Contract No.: AMA Health Policy H-440.842 (2013). https://policysearch.ama-
assn.org/policyﬁnder/detail/H-440.842?utrl=%2FAMADoc%2FHOD.xml-0-38-
58.xml.
3. WHO. World Health Organization depression fact sheet number 369 (2015).
https://www.who.int/en/news-room/fact-sheets/detail/depression.
4. NCHS. Health United States, 2016: With Chartbook on Long-term Trends in
Health (National Center for Health Statistics, Centers for Disease Control and
Prevention, U.S. D.H.H.S., Hyattsville, 2017)
5. Stunkard, A. J., Fernstrom, M. H., Price, A., Frank, E. & Kupfer, D. J. Direction of
weight change in recurrent depression. Consistency across episodes. Arch.
Gen. Psychiatry 47, 857–860 (1990).
6. Markowitz, S., Friedman, M. A. & Arent, S. M. Understanding the relation
between obesity and depression: causal mechanisms and implications for
treatment. Clin. Psychol. 15, 1–20 (2008).
7. Onyike, C. U., Crum, R. M., Lee, H. B., Lyketsos, C. G. & Eaton, W. W. Is obesity
associated with major depression? Results from the Third National Health and
Nutrition Examination Survey. Am. J. Epidemiol. 158, 1139–1147 (2003).
8. Richardson, L. P. et al. A longitudinal evaluation of adolescent depression and
adult obesity. Arch. Pediatr. Adolesc. Med. 157, 739–745 (2003).
9. Bjorntorp, P. Do stress reactions cause abdominal obesity and comorbidities?
Obes. Rev. 2, 73–86 (2001).
10. Dannon, P. N. et al. A naturalistic long-term comparison study of selective
serotonin reuptake inhibitors in the treatment of panic disorder. Clin. Neuro-
pharmacol. 30, 326–334 (2007).
11. Sussman, N., Ginsberg, D. L. & Bikoff, J. Effects of nefazodone on body weight:
a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-
controlled trials. J. Clin. Psychiatry 62, 256–260 (2001).
12. Michelson, D. et al. Changes in weight during a 1-year trial of ﬂuoxetine. Am. J.
Psychiatry 156, 1170–1176 (1999).
13. Ferguson, J. M. SSRI antidepressant medications: adverse effects and toler-
ability. Prim. Care Companion J. Clin. Psychiatry 3, 22–27 (2001).
Lee et al. Translational Psychiatry            (2019) 9:10 Page 11 of 12
14. Goldstein, B. J. & Goodnick, P. J. Selective serotonin reuptake inhibitors in the
treatment of affective disorders--III. Tolerability, safety and pharmacoeco-
nomics. J. Psychopharmacol. 12, S55–S87 (1998).
15. Mackay, F. J. et al. A comparison of ﬂuvoxamine, ﬂuoxetine, sertraline and
paroxetine examined by observational cohort studies. Pharmacoepidemiol
Drug Saf. 6, 235–246 (1997).
16. Mastronardi, C. et al. Long-term body weight outcomes of antidepressant-
environment interactions. Mol. Psychiatry 16, 265–272 (2011).
17. Subhash Peter, M. C. Understanding the adaptive response in vertebrates: the
phenomenon of ease and ease response during post-stress acclimation. Gen.
Comp. Endocrinol. 181, 59–64 (2013).
18. Pagliassotti, M. J., Knobel, S. M., Shahrokhi, K. A., Manzo, A. M. & Hill, J. O. Time
course of adaptation to a high-fat diet in obesity-resistant and obesity-prone
rats. Am. J. Physiol. 267, R659–R664 (1994).
19. Team, R. C. R. A language and environment for statistical computing. R Foun-
dation for Statistical Computing, Vienna (2017).
20. McAllister, E. J. et al. Ten putative contributors to the obesity epidemic. Crit.
Rev. Food Sci. Nutr. 49, 868–913 (2009).
21. File, S. E. & Tucker, J. C. Behavioral consequences of antidepressant treatment
in rodents. Neurosci. Biobehav Rev. 10, 123–134 (1986).
22. Watanabe, Y., Gould, E. & McEwen, B. S. Stress induces atrophy of apical
dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 588, 341–345
(1992).
23. Baron, J. et al. Catch-up growth after glucocorticoid excess: a mechanism
intrinsic to the growth plate. Endocrinology 135, 1367–1371 (1994).
24. Ortuno, M. J. et al. Serotonin-reuptake inhibitors act centrally to cause bone
loss in mice by counteracting a local anti-resorptive effect. Nat. Med. 22,
1170–1179 (2016).
25. Luther, J. & David, J. P. Bone and adipose tissue formation. Z. Rheumatol. 75,
701–706 (2016).
26. Whitﬁeld, J. F. Leptin: brains and bones. Expert Opin. Investig. Drugs 10,
1617–1622 (2001).
27. Cornish, J. et al. Leptin directly regulates bone cell function in vitro and
reduces bone fragility in vivo. J. Endocrinol. 175, 405–415 (2002).
28. Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a
central control of bone mass. Cell 100, 197–207 (2000).
29. Shi, Y. et al. Dissociation of the neuronal regulation of bone mass and energy
metabolism by leptin in vivo. Proc. Natl. Acad. Sci. Usa. 105, 20529–20533
(2008).
30. Yadav, V. K. et al. A serotonin-dependent mechanism explains the leptin
regulation of bone mass, appetite, and energy expenditure. Cell 138, 976–989
(2009).
31. Wu, Y., Sun, H., Yakar, S. & LeRoith, D. Elevated levels of insulin-like growth
factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice.
Endocrinology 150, 4395–4403 (2009).
32. Elis, S. et al. Elevated serum levels of IGF-1 are sufﬁcient to establish normal
body size and skeletal properties even in the absence of tissue IGF-1. J. Bone
Miner. Res. 25, 1257–1266 (2010).
33. Corpas, E., Harman, S. M. & Blackman, M. R. Human growth hormone and
human aging. Endocr. Rev. 14, 20–39 (1993).
34. Iranmanesh, A., Lizarralde, G. & Veldhuis, J. D. Age and relative adiposity are
speciﬁc negative determinants of the frequency and amplitude of growth
hormone (GH) secretory bursts and the half-life of endogenous GH in healthy
men. J. Clin. Endocrinol. Metab. 73, 1081–1088 (1991).
35. Sjögren, K. et al. Effects of liver-derived Insulin-like Growth Factor-I on bone
metabolism in mice. J. Bone Mineral. Res. 17, 1977–1987 (2002).
36. Serretti, A. & Mandelli, L. Antidepressants and body weight: a comprehensive
review and meta-analysis. J. Clin. Psychiatry 71, 1259–1272 (2010).
37. Malhi, G. S., Mitchell, P. B. & Caterson, I. ‘Why getting fat, Doc?’Weight gain and
psychotropic medications. Aust. N. Z. J. Psychiatry 35, 315–321 (2001).
38. Andersen, S. W., Clemow, D. B. & Corya, S. A. Long-term weight gain in
patients treated with open-label olanzapine in combination with
ﬂuoxetine for major depressive disorder. J. Clin. Psychiatry 66,
1468–1476 (2005).
39. Montgomery, S. A., Reimitz, P. E. & Zivkov, M. Mirtazapine versus amitriptyline
in the long-term treatment of depression: a double-blind placebo-controlled
study. Int Clin. Psychopharmacol. 13, 63–73 (1998).
40. Dannon, P. N. et al. Three year naturalistic outcome study of panic disorder
patients treated with paroxetine. BMC Psychiatry 4, 16 (2004).
41. Coppen, A. et al. Continuation therapy with amitriptyline in depression. Br. J.
Psychiatry 133, 28–33 (1978).
42. Michelson, D. et al. Bone mineral density in women with depression. N. Engl. J.
Med. 335, 1176–1181 (1996).
43. Yazici, K. M., Akinci, A., Sutcu, A. & Ozcakar, L. Bone mineral density in pre-
menopausal women with major depressive disorder. Psychiatry Res. 117,
271–275 (2003).
44. Kahl, K. G. et al. Bone mineral density, markers of bone turnover, and cytokines
in young women with borderline personality disorder with and without
comorbid major depressive disorder. Am. J. Psychiatry 162, 168–174 (2005).
45. Yirmiya, R. et al. Depression induces bone loss through stimulation of the
sympathetic nervous system. Proc. Natl. Acad. Sci. Usa. 103, 16876–16881
(2006).
46. Amin, S., Achenbach, S. J., Atkinson, E. J., Khosla, S. & Melton, L. J. III Trends in
fracture incidence: a population-based study over 20 years. J. Bone Miner. Res.
29, 581–589 (2014).
47. Cooper, C., Campion, G. & Melton, L. J. III Hip fractures in the elderly: a world-
wide projection. Osteoporos. Int. 2, 285–289 (1992).
48. Brommage, R. et al. Adult Tph2 knockout mice without brain serotonin have
moderately elevated spine trabecular bone but moderately low cortical bone
thickness. Bone. Rep. 4, 718 (2015).
Lee et al. Translational Psychiatry            (2019) 9:10 Page 12 of 12
